Drug intelligence / Profile preview

UPV-204

Development stage: Preclinical
Lead developer: UbiVac
Modality: Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

UPV-204 is a preclinical-stage drug initially developed by UbiVac, Inc. It is being investigated for its potential in treating neoplasms, with a specific focus on malignant melanoma. The drug functions as an immunostimulant, falling under the categories of cancer vaccines and protein vaccines, and involves ubiquitins in its mechanism of action.

Beyond the preview

Go deeper on UPV-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UPV-204.

Explore the full profile